AstraZeneca (AZN) Tops Q2 EPS by $1.16, Reiterates Guidance

AstraZeneca (NASDAQ: AZN) reported Q2 EPS of $2.15, $1.16 better than the analyst estimate of $0.99. Revenue for the quarter came in at $11.42 billion versus the consensus estimate of $11.02 billion.

The Company reiterates guidance for FY 2023 at CER, based on the average foreign exchange rates through 2022.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• AbbVie updates 2026 EPS guidance after $291M IPR&D charge
• Digital Brands Group retains law firm and data firm over stock manipulation concerns
• Samsung 2q Oper Profit 89.40t Won, Est. 84.2t Won